Not a good buy right now for an impatient trader: no Intellectia buy signals, weak/uncertain trend setup, and statistical drift points lower over the next week/month.
Pre-market weakness (3.82, -2.05%) below the pivot (4.074) keeps the stock in a vulnerable zone unless it quickly reclaims ~4.07.
With no near-term catalysts/news and no financial/valuation visibility provided, there isn’t enough to justify an immediate entry; bias is to avoid or exit.
Momentum: MACD histogram slightly positive (0.0049) but positively contracting → bullish momentum is fading rather than strengthening.
RSI(6) = 38.39 → leaning weak (not oversold enough to imply a strong mean-reversion buy signal), consistent with a soft tape.
Moving averages converging → no clear trend; typically implies chop/range and lower-quality entries.
Pattern-based projection provided: ~+1.31% next day (60% chance) but -2.5% next week and -3.72% next month → near-term bounce possible, but broader bias negative.
Positive Catalysts
and quickly reclaims the pivot (~4.07), opening room toward ~4.
Very short-term model read suggests a modest next-day upside scenario (though not strong enough alone to act on).
Neutral/Negative Catalysts
MACD momentum is weakening (contracting histogram), and RSI remains on the weaker side.
Financial Performance
Financial snapshot unavailable (data error: "list index out of range"), so latest quarter/season growth trends cannot be assessed from the provided data.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, implying limited/absent recent coverage in this dataset.
Wall Street pro/con view cannot be robustly summarized here due to missing analyst inputs; based on available trading/technical data alone, conviction for a buy is low.
Wall Street analysts forecast CHNR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHNR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CHNR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHNR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
